RxDoctor Payments Data

Danny McFall, MD

Internal Medicine · Florence, ALNPI 1023129814

Payments from drug & device makers

$2,582in general payments, 2019–2025

Across 165 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$421
  • Merck$400
  • Boehringer Ingelheim$314
  • Lilly USA, LLC$205
  • Amarin Pharma, Inc.$167
  • GSK$152
  • plus $923 from 17 others

What the payments were for

  • Food & beverage$2,582100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,582 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$168,902
Medicare patients
455
Services billed
9,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban452$343,717
OzempicSemaglutide151$168,229
JardianceEmpagliflozin161$155,098
MounjaroTirzepatide88$133,523
FarxigaDapagliflozin Propanediol87$62,549
XareltoRivaroxaban59$58,473
TrulicityDulaglutide32$40,326
EntrestoSacubitril/Valsartan44$35,852
Repatha SureclickEvolocumab33$34,729
LinzessLinaclotide36$33,711
JanuviaSitagliptin Phosphate40$31,450
Potassium Chloride700$16,465
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate14$14,700
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$13,065
Atorvastatin Calcium970$12,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Premarin$421$351,781501 claims
Lilly USA, LLCMounjaro, Trulicity$205$173,849120 claims
Novo NordiskOzempic$83$168,229151 claims
Boehringer IngelheimJardiance, Combivent Respimat$314$164,957182 claims
AstraZenecaFarxiga$25$62,54987 claims
Johnson & JohnsonXarelto$127$58,47359 claims
MerckJanuvia, Lagevrio (Eua)$400$38,07154 claims
NovartisEntresto$134$35,85244 claims
AbbVieLinzess$104$33,71136 claims
GSKAnoro Ellipta$152$5,82313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Florence

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →